KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Long-Term Debt Repayments (2016 - 2025)

AbbVie (ABBV) has disclosed Long-Term Debt Repayments for 11 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Debt Repayments fell 99.86% to $8.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.8 billion, a 29.29% decrease, with the full-year FY2025 number at $6.8 billion, down 29.29% from a year prior.
  • Long-Term Debt Repayments was $8.0 million for Q4 2025 at AbbVie, down from $9.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $6.9 billion in Q4 2022 to a low of $2.0 million in Q2 2022.
  • A 5-year average of $2.3 billion and a median of $2.2 billion in 2021 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: crashed 99.94% in 2022, then soared 50000.0% in 2023.
  • AbbVie's Long-Term Debt Repayments stood at $3.8 billion in 2021, then surged by 82.6% to $6.9 billion in 2022, then crashed by 73.81% to $1.8 billion in 2023, then surged by 221.18% to $5.8 billion in 2024, then crashed by 99.86% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Long-Term Debt Repayments are $8.0 million (Q4 2025), $9.0 million (Q3 2025), and $3.8 billion (Q2 2025).